Novo Nordisk Invests €432 mn in Ireland
Last update: March 2, 2026
Disclaimer: This website may contain affiliate links, which means we may earn a commission if you click on the link and make a purchase. We only recommend products or services that we personally use and believe will add value to our readers. Your support is appreciated!
The firm which is waiting for approval for it Anti-obesity Pills says investment in the Irish plant will help meet demands...
Danish drugmaker Novo Nordisk said on Monday it would invest 432 million euros to expand its manufacturing plant in Ireland, as it prepares for anticipated European approval of a pill version of its anti-obesity treatment Wegovy.
“With the investment in the Athlone facility, Novo Nordisk is expanding its production capacities for oral products, which will strengthen our ability to meet both current and future demand, outside the U.S.,” Kasper Bodker Mejlvang, Executive Vice President for Chemistry, Manufacturing and Controls and Product Supply, said in a statement.
The company’s semaglutide drug, marketed as Ozempic for diabetes and Wegovy for obesity, is among the world’s best-selling medicines.
Until recently, semaglutide had only been available as an injection. A pill form of Wegovy was authorised in the United States in early 2026 and is now awaiting regulatory approval in Europe, which the company expects in the second half of the year.
According to the World Health Organization, 22.6% of adults in Europe are obese.
Novo Nordisk said construction linked to the expansion in Athlone had already begun and would be completed in phases through 2028.
